Yıl: 2010 Cilt: 38 Sayı: 4 Sayfa Aralığı: 244 - 249 Metin Dili: Türkçe

Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow

Öz:
Amaç: Koroner yavaş akım (KYA) olan hastalarda oksidatif stres ile antioksidan savunma arasında dengesizlik gösterilmiştir. Bu çalışmada, KYA hastalarında nebivolol tedavisinin oksidatif stres parametreleri üzerine etkisi araştırıldı.Çalışma planı: Çalışmaya KYA saptanan 32 hasta (10 kadın, 22 erkek; ort. yaş 53.3±5.2) ve anjiyografide koroner arterleri normal bulunan 32 kontrol (14 kadın, 18 erkek; ort. yaş 50.6±5.2) alındı. Koroner yavaş akım TIMI kare sayısı yöntemiyle belirlendi. Koroner yavaş akım olan hastalara altı ay süreyle 5 mgr/gün dozunda nebivolol tedavisi uygulandı. Kontrol grubundan ve KYA hastalarından başlangıçta ve altı ay süreyle nebivolol tedavisi sonrasında alınan kan örneklerinde malondialdehit (MDA) ve serum nitrik oksit (NO) düzeyleri, eritrosit katalaz (CAT) ve eritrosit süperoksit dismutaz aktiviteleri (SOD) ölçüldü.Bulgular: İki grup yaş, beden kütle indeksi, kan basıncı, kalp hızı ve lipit profili yönünden benzer özelliklerdeydi. Koroner yavaş akım grubunda sigara içme kontrollere göre daha yaygındı. Sol ön inen, sirkumfleks ve sağ koroner arterlerden ölçülen TIMI kare sayıları KYA grubunda anlamlı derecede fazla bulundu (p<0.0001). Kan incelemesinde başlangıç MDA ve NO düzeyleri ve SOD ve CAT aktiviteleri iki grup arasında anlamlı farklılık gösterdi; MDA KYA grubunda anlamlı derecede artmış bulunurken (p<0.0001), SOD (p<0.0001), CAT (p<0.001) ve NO (p<0.001) anlamlı derecede düşük değerler sergiledi. Nebivolol tedavisi sonrasında altıncı ayda oksidatif stres parametrelerinin tümünde başlangıç değerlerine göre anlamlı düzelmeler görüldü (MDA, SOD, CAT, ve NO için p<0.0001). Bu parametrelerin hepsi kontrol grubundaki değerlere yaklaşmıştı.Sonuç: Bulgularımız nebivolol tedavisinin, aterosklerozun erken evresi olarak kabul edilen KYA’da oksidatif stres parametrelerinin iyileştirilmesinde yararlı olabileceğini göstermektedir.
Anahtar Kelime:

Koroner yavaş akım olan hastalarda nebivolol tedavisinin oksidatif stres parametreleri üzerine olumlu etkileri

Öz:
Objectives: Imbalance between oxidative stress and antioxidant defense has been demonstrated in patients with slow coronary flow (SCF). The aim of this study was to investigate the effect of nebivolol treatment on oxidative stress parameters in SCF patients. Study design: The study included 32 patients (10 females, 22 males; mean age 53.3±5.2 years) with SCF and 32 control subjects (14 females, 18 males; mean age 50.6±5.2 years) with normal coronary arteries on angiography. Coronary slow flow was determined by the TIMI frame count method. Patients with SCF received nebivolol treatment (5 mg/day) for six months. Blood samples were analyzed for malondialdehyde (MDA) and serum nitric oxide (NO) levels, and erythrocyte catalase (CAT) and erythrocyte superoxide dismutase (SOD) activities in the control group and, in SCF patients, at baseline and after six months of nebivolol treatment.Results: The two groups were similar with respect to age, body mass index, blood pressure, heart rate, and lipid profile. Smoking was more frequent in the SCF group compared to the controls. TIMI frame counts measured from the left anterior descending, circumflex, and right coronary arteries were significantly higher in the SCF group (p<0.0001). Baseline MDA and NO levels, and SOD and CAT activities were significantly different between the two groups, with significantly increased MDA (p<0.0001), and significantly decreased SOD (p<0.0001), CAT (p<0.001), and NO (p<0.001) in the SCF group. After six months of nebivolol treatment, all oxidative stress parameters showed significant improvements compared to the baseline values (p<0.0001 for MDA, SOD, CAT, and NO) and approximated to the values of the control group.Conclusion: Our results show that nebivolol treatment may be beneficial to improve oxidative stress parameters in patients with SCF, which is considered to be an early stage of atherosclerosis.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding. Am Heart J 1972;84:66-71.
  • 2. Kaski JC, Tousoulis D, Galassi AR, McFadden E, Pereira WI, Crea F, et al. Epicardial coronary artery tone and reactivity in patients with normal coronary arteriograms and reduced coronary flow reserve (syndrome X). J Am Coll Cardiol 1991;18:50-4.
  • 3. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986;74:964-72.
  • 4. Tanrıverdi H, Evrengül H, Kuru O, Tanrıverdi S, Seleci D, Enli Y, et al. Cigarette smoking-induced oxidative stress may impair endothelial function and coronary blood flow in angiographically normal coronary arteries. Circ J 2006;70:593-9.
  • 5. Sezgin AT, Sığırcı A, Barutçu İ, Topal E, Sezgin N, Özdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14:155-61.
  • 6. Yaymacı B, Dağdelen S, Bozbuğa N, Demirkol O, Say B, Güzelmeriç F, et al. The response of the myocardial metabolism to atrial pacing in patients with coronary slow flow. Int J Cardiol 2001;78:151-6.
  • 7. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478.
  • 8. Li JJ, Qin XW, Li ZC, Zeng HS, Gao Z, Xu B, et al. Increased plasma C reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta 2007;385:43-7.
  • 9. Enli Y, Türk M, Akbay R, Evrengül H, Tanrıverdi H, Kuru O, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther 2008;25:37-44.
  • 10. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990;186:421-31.
  • 11. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 1987;45:337 51.
  • 12. Çelik T, İyisoy A, Kursaklıoğlu H, Kardeşoğlu E, Kılıç S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-6.
  • 13. Strålin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995;15:2032-6.
  • 14. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
  • 15. Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens 2006;8(8 Suppl 2):31-8.
  • 16. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004;1:2-16.
  • 17. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112:1198-205.
  • 18. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005;23:589-96.
  • 19. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801.
  • 20. Kuroedov A, Cosentino F, Lüscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004;22:155-68.
  • 21. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
  • 22. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT. Intrathoracic spatial location of specified coronary segments on the normal human heart. Applications in quantitative arteriography, assessment of regional risk and contraction, and anatomic display. Circulation 1988;78(5 Pt 1):1167-80.
  • 23. Fridovich I. Superoxide radical: an endogenous toxicant. Annu Rev Pharmacol Toxicol 1983;23:239-57.
  • 24. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
  • 25. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, Heyndrickx GR, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but “normal” coronary angiography. Circulation 2001; 104:2401 6.
  • 26. Cin VG, Pekdemir H, Camsar A, Çiçek D, Akkuş MN, Parmaksız T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003; 44:907-19.
  • 27. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 1998;18:157-67.
  • 28. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511-4.
  • 29. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148-53.
  • 30. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
  • 31. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frölich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000; 50:377-9.
APA AKÇAY A, ACAR G, KURUTAŞ E, SÖKMEN A, ATLI Y, NACAR A, TUNCER C (2010). Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Türk Kardiyoloji Derneği Arşivi, 38(4), 244 - 249.
Chicago AKÇAY Ahmet,ACAR Gürkan,KURUTAŞ Ergül,SÖKMEN ABDULLAH,ATLI Yalçın,NACAR Ahmet Buğra,TUNCER Cemal Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Türk Kardiyoloji Derneği Arşivi 38, no.4 (2010): 244 - 249.
MLA AKÇAY Ahmet,ACAR Gürkan,KURUTAŞ Ergül,SÖKMEN ABDULLAH,ATLI Yalçın,NACAR Ahmet Buğra,TUNCER Cemal Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Türk Kardiyoloji Derneği Arşivi, vol.38, no.4, 2010, ss.244 - 249.
AMA AKÇAY A,ACAR G,KURUTAŞ E,SÖKMEN A,ATLI Y,NACAR A,TUNCER C Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Türk Kardiyoloji Derneği Arşivi. 2010; 38(4): 244 - 249.
Vancouver AKÇAY A,ACAR G,KURUTAŞ E,SÖKMEN A,ATLI Y,NACAR A,TUNCER C Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Türk Kardiyoloji Derneği Arşivi. 2010; 38(4): 244 - 249.
IEEE AKÇAY A,ACAR G,KURUTAŞ E,SÖKMEN A,ATLI Y,NACAR A,TUNCER C "Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow." Türk Kardiyoloji Derneği Arşivi, 38, ss.244 - 249, 2010.